Evidence map›Paper›PMID 26819314›Full record

ArticleJournal of virology2016

Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor.

Takayuki Murata, Chieko Noda, Yohei Narita, Takahiro Watanabe, Masahiro Yoshida, Keiji Ashio, Yoshitaka Sato, Fumi Goshima, Teru Kanda, Hironori Yoshiyama and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Chromatin Control of EBV Infection and Latency.Current topics in microbiology and immunology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Characterization of a SuppressiveFrontiers in microbiology · 2017
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Takayuki MurataDepartment of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan tmurata@med.nagoya-u.ac.jp.
Chieko NodaDivision of Virology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan.
Yohei NaritaDepartment of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Takahiro WatanabeDepartment of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Masahiro YoshidaDepartment of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Keiji AshioDepartment of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Yoshitaka SatoDepartment of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Fumi GoshimaDepartment of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Teru KandaDivision of Virology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan.
Hironori YoshiyamaResearch Center for Infection-associated Cancer, Institute for Genetic Medicine, Hokkaido University, Kita-ku, Sapporo, Japan.
Tatsuya TsurumiDivision of Virology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan.
Hiroshi KimuraDepartment of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Nagoya University · JPAichi Cancer Center · JPShimane University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledLatent membrane protein 1 (LMP1) is a major oncogene essential for primary B cell transformation by Epstein-Barr virus (EBV). Previous studies suggested that some transcription factors, such as PU.1, RBP-Jκ, NF-κB, and STAT, are involved in this expression, but the underlying mechanism is unclear. Here, we identified binding sites for PAX5, AP-2, and EBF in the proximal LMP1 promoter (ED-L1p). We first confirmed the significance of PU.1 and POU domain transcription factor binding for activation of the promoter in latency III. We then focused on the transcription factors AP-2 and early B cell factor (EBF). Interestingly, among the three AP-2-binding sites in the LMP1 promoter, two motifs were also bound by EBF. Overexpression, knockdown, and mutagenesis in the context of the viral genome indicated that AP-2 plays an important role in LMP1 expression in latency II in epithelial cells. In latency III B cells, on the other hand, the B cell-specific transcription factor EBF binds to the ED-L1p and activates LMP1 transcription from the promoter. IMPORTANCE: Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is crucial for B cell transformation and oncogenesis of other EBV-related malignancies, such as nasopharyngeal carcinoma and T/NK lymphoma. Its expression is largely dependent on the cell type or condition, and some transcription factors have been implicated in its regulation. However, these previous reports evaluated the significance of specific factors mostly by reporter assay. In this study, we prepared point-mutated EBV at the binding sites of such transcription factors and confirmed the importance of AP-2, EBF, PU.1, and POU domain factors. Our results will provide insight into the transcriptional regulation of the major oncogene LMP1.

Indexed as

Gene Expression Regulation, ViralBinding SitesCell Transformation, ViralHEK293 CellsHeLa CellsHerpesvirus 4, HumanHumansMutationOncogenesPOU Domain FactorsPromoter Regions, GeneticProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Trans-ActivatorsTranscription Factor AP-2Viral Matrix ProteinsEBF1 protein, humanEBV-associated membrane antigen, Epstein-Barr virusPOU Domain FactorsProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Trans-ActivatorsTranscription Factor AP-2Viral Matrix Proteins

Identifiers

PMID26819314
PMCPMC4810554
OpenAlexW2335183436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.